Combining chronic remote ischemic conditioning and mindfulness to lower heart events after incomplete coronary revascularization

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study tests whether combining chronic remote ischemic conditioning (CRIC) with mindfulness therapy (MFT) reduces cardiovascular adverse events in patients with incomplete coronary revascularization. Participants receive active or sham versions of CRIC and MFT and are followed for heart-related outcomes and symptoms. Eligible adults have coronary artery disease with at least one vessel showing >90% stenosis and a QFR < 0.80 plus ischemic symptoms. The trial is run at Fuwai Central China Cardiovascular Hospital in Zhengzhou, Henan.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\) Age ≥18 years old
* 2\) Consistent with the diagnosis of coronary heart disease, complete revascularization was not performed (coronary angiography showed that at least one vessel with a reference diameter of 3.0mm had stenosis greater than 90%, and quantitative flow ratio (QFR) \< 0.80)
* 3\) Symptoms of myocardial ischemia (resting or exertional angina; Angina allele: chest tightness, shortness of breath, etc.);

Exclusion Criteria:

* Age \< 18 years old
* Heart failure patients with NYHA class IV, or left ventricular ejection fraction (LVEF) \< 30%
* Creatinine clearance \<15 mL/min (or eGFR \< 15 mL/min/1.73m²), or requires dialysis
* Myocardial diseases such as hypertrophic cardiomyopathy, dilated cardiomyopathy, etc.
* Uncontrolled or recurrent arrhythmic events (e.g., ventricular fibrillation, recurrent or symptomatic sustained ventricular tachycardia, complete heart block, atrial fibrillation with rapid ventricular rates, supraventricular tachycardia refractory to drugs)
* Poorly controlled hypertension (SBP \> 180 mm Hg or DBP \> 110 mm Hg)
* Active liver disease or persistent ALT or AST elevation ≥ 3 times the upper limit of normal
* Unexplained CK \> 5 times the upper limit of normal, or elevated CK due to known muscle disease
* Planned or anticipated cardiac surgery or revascularization before randomization
* History of active malignancy (surgery, radiation therapy, and/or systemic therapy within the past 3 years)
* Diagnosed or suspected upper extremity vascular malformations, aneurysms, arteriovenous fistulas, or thrombosis
* Hearing impairment, unable to undergo mindfulness therapy
* Currently participating in another drug or device study, or within 30 days of completing another drug or device study or receiving another investigational drug
* Any life-threatening comorbid conditions expected to result in death within the next year (excluding cardiovascular diseases)
* Alcoholism, substance abuse history; and unwilling or unable to stop alcohol or substance abuse during the study
* History of major organ transplant (e.g., lung, liver, heart, bone marrow, kidney)
* Investigator's judgment of known major active and uncontrolled disease, or any medical, physical, or surgical conditions (e.g., infection, significant blood, kidney, metabolic, gastrointestinal, or endocrine dysfunction) that may interfere with participation in the clinical study
* As known to the investigator, the subject is unlikely to complete follow-up for more than 1 year or is expected to be unable to comply with the study requirements or understand the study's objectives and potential risks.

Where it's running

• Fuwai Central China Cardiovascular Hospital
  Zhengzhou, Henan, China Recruiting

Study contacts

• Study coordinator: Quan Guo, MD
• Email: xinyiguoquan@163.com
• Phone: 15670510031

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease

  This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.

  Recruiting Centro Cardiologico Monzino · Cosenza, CS and 3 other locations · NCT07917234

• Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents

  This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.

  Recruiting Adiyaman University · Adıyaman · NCT07898215

• Can preoperative photon-counting CT help predict heart recovery after bypass surgery?

  This observational study tests whether a preoperative photon-counting CT can help predict heart function 3 months after coronary bypass surgery in adults with coronary artery disease.

  Recruiting Chinese PLA General Hospital · Beijing · NCT07883499

• Real-World Drug-Coated Balloon Angioplasty in Coronary Artery Disease

  This registry tests how drug-coated balloons perform in everyday clinical practice for adults with coronary artery disease undergoing PCI.

  Recruiting at 5 sites Hospital Arnau de Vilanova · Mexico City, Mexico City and 4 other locations · NCT07875088

• Predicting vasopressor needs after anesthesia in elective on-pump CABG using dynamic arterial elastance

  This study tests whether EaDyn measured after induction can help predict which patients will need vasopressors during elective on-pump CABG.

  Recruiting University of Gaziantep · Gaziantep · NCT07871201

• Intraoperative Pulse Pressure Variation and Postoperative Lactate Clearance in CABG Patients

  This study tests whether the amount a patient’s pulse pressure varies during surgery relates to how quickly lactate levels drop after CABG.

  Recruiting University of Gaziantep · Gaziantep · NCT07871188

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.